Summary

The 7 major dementia markets reached a value of US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 12.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.85% during 2024-2034.

The dementia market has been comprehensively analyzed in IMARC's new report titled "Dementia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dementia is a progressive syndrome that affects cognitive function, particularly memory, thinking, and reasoning. It is caused by damage to or degeneration of brain cells and can lead to a decline in a person's ability to perform daily activities and communicate effectively. The most common symptoms of this ailment include memory loss, fluctuations in mood and behavior, difficulty with language and communication, etc. Individuals with dementia may have trouble performing routine tasks, such as getting dressed or preparing meals, and may experience personality changes, confusion, and disorientation. Diagnosing dementia involves a combination of medical evaluation, cognitive assessments, and diagnostic testing. A healthcare professional will typically begin by conducting a thorough medical history, physical examination, and cognitive testing to assess memory, language, and problem-solving abilities. Several additional diagnostic procedures, including brain imaging and blood tests, may also be ordered to help rule out other possible causes of cognitive decline.

The increasing cases of traumatic brain injuries and the growing prevalence of neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease, are primarily driving the dementia market. In addition to this, the rising incidences of several associated risk factors, including advancing age, genetic mutations, high blood pressure, buildup of abnormal protein deposits in the brain, etc., are also bolstering the market growth. Furthermore, the widespread adoption of antipsychotic medications, such as risperidone, olanzapine, quetiapine, etc., to treat symptoms like agitation, aggression, and hallucinations that often accompany the ailment is acting as another significant growth-inducing factor. Additionally, the inflating utilization of cholinesterase inhibitors, which work by increasing the levels of neurotransmitter acetylcholine in the brain, is further augmenting the market growth. Moreover, the escalating demand for non-pharmacological interventions, including cognitive stimulation therapy, music therapy, physical exercise, etc., to enhance cognitive function, mood, and behavior is also creating a positive outlook for the market. Apart from this, the introduction of advanced imaging techniques that detect changes in the brain's structure and function, such as the accumulation of amyloid plaques and tau tangles, is expected to drive the dementia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the dementia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dementia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dementia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dementia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dementia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dementia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the dementia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the dementia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the dementia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of dementia across the seven major markets?
What is the number of prevalent cases (2018-2034) of dementia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of dementia by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of dementia by type across the seven major markets?
How many patients are diagnosed (2018-2034) with dementia across the seven major markets?
What is the size of the dementia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of dementia?
What will be the growth rate of patients across the seven major markets?

Dementia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for dementia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dementia market?
What are the key regulatory events related to the dementia market?
What is the structure of clinical trial landscape by status related to the dementia market?
What is the structure of clinical trial landscape by phase related to the dementia market?
What is the structure of clinical trial landscape by route of administration related to the dementia market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Dementia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034​)
4.4 Market Overview (2018-2023) and Forecast (2024-2034​)
4.5 Competitive Intelligence

5 Dementia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Dementia - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034​)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034​)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034​)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034​)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034​)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034​)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034​)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034​)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)

8 Dementia - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Dementia - Unmet Needs

10 Dementia - Key Endpoints of Treatment

11 Dementia - Marketed Products
11.1 List of Dementia Marketed Drugs Across the Top 7 Markets
11.1.1 Aricept (Donepezil) - Eisai
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Exelon (Rivastigmine) - Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Razadyne (Galantamine) - Janssen/Sanochemia Pharmazeutika
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Namenda (Memantine) - Merz Pharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Namzaric (Donepezil/memantine extended release) - Adamas Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Dementia - Pipeline Drugs
12.1 List of Dementia Pipeline Drugs Across the Top 7 Markets
12.1.1 PR006 - Prevail Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 DNL593 - Denali Therapeutics Inc
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 PBFT02 - Passage Bio
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 CT1812 - Cognition Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 IGCAD1 - IGC pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Dementia - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Dementia – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Dementia - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dementia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034​)
15.2.2 Dementia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034​)
15.3 Market Scenario - United States
15.3.1 Dementia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034​)
15.3.2 Dementia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034​)
15.3.3 Dementia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dementia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034​)
15.4.2 Dementia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034​)
15.4.3 Dementia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dementia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034​)
15.5.2 Dementia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034​)
15.5.3 Dementia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dementia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034​)
15.6.2 Dementia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034​)
15.6.3 Dementia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dementia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034​)
15.7.2 Dementia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034​)
15.7.3 Dementia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dementia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034​)
15.8.2 Dementia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034​)
15.8.3 Dementia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dementia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034​)
15.9.2 Dementia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034​)
15.9.3 Dementia - Access and Reimbursement Overview

16 Dementia - Recent Events and Inputs From Key Opinion Leaders

17 Dementia Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Dementia Market – Strategic Recommendations

19 Appendix